API SUPPLIERS

API Suppliers

0

US DMFs Filed

0

CEP/COS Certifications

0

JDMFs Filed

0

Other Certificates

0

Other Suppliers

0

API REF. PRICE (USD / KG)

0

API Market Place

0

INTERMEDIATES

0

DOSSIERS // FDF

USA (Orange Book)

0

Europe

0

Canada

0

Australia

0

South Africa

0

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

FDF Market Place

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Full Screen View

H. Lundbeck AS

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Denovo Biopharma In-Licenses Late-Stage Alzheimer's Disease Asset from Lundbeck

Details:

Lundbeck gets options to re-acquire idalopirdine for predetermined undisclosed financial terms, with Denovo and Lundbeck sharing China rights in the event Lundbeck's options are exercised and Denovo retaining all global rights in the event Lundbeck's options are not exercised.

Lead Product(s): Idalopirdine

Therapeutic Area: Neurology Product Name: DB109

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Denovo Biopharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement July 01, 2021

ASK
US